Y-mAbs Therapeutics, Inc.Y-mAbs Therapeutics, Inc.Y-mAbs Therapeutics, Inc.

Y-mAbs Therapeutics, Inc.

No trades
See on Supercharts

YMAB fundamentals

Y-mAbs Therapeutics, Inc. financial statements, including revenue, expenses, profit, and loss

The total revenue of YMAB for the last quarter is 18.46 M USD, and it's 19.02% lower compared to the previous quarter. The net income of Q3 24 is -7.00 M USD.

Q3 '17
Q4 '17
Q3 '18
Q4 '18
Q1 '19
Q2 '19
Q3 '19
Q4 '19
Q1 '20
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: USD
Q3 '17
Q4 '17
Q3 '18
Q4 '18
Q1 '19
Q2 '19
Q3 '19
Q4 '19
Q1 '20
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
TTM
Total revenueYoY growth
Gross profitYoY growth
Pretax incomeYoY growth
Net incomeYoY growth
EBITDAYoY growth
EBITYoY growth